{"schema_version":"secwatch.filing_event.v1","accession":"0001493152-24-045354","form_type":"8-K","ticker":"AWHL","cik":"0000926617","company_name":"Aspira Women's Health Inc.","filed_at":"2024-11-14T23:59:59+00:00","discovered_at":"2026-05-14T18:03:11.415453+00:00","generated_at":"2026-05-30T00:43:14.024271+00:00","sec_items":["2.02","9.01"],"event_type":"earnings","sentiment":"neutral","materiality_score":0.55,"calibrated_materiality_score":0.55,"confidence":"high","headline":"Aspira Women's Health Q3 rev $2.3M, cash burn $2.9M, reaffirms FY 2024 cash guidance","bullets":["Q3 OvaSuite revenue $2.3M (+2% YoY); test volume 6,001 units (+4% YoY).","OvaWatch volume grew 27% YoY, now 22% of total test volume.","Cash used in ops $2.9M, down 12% from Q2; FY 2024 cash burn guidance reaffirmed $13.0-14.5M.","Awarded $10M ARPA-H contract for ENDOinform; expects first $2M payment by year-end.","Gross margin 60% (vs 59% YoY); sales & marketing up 26% but G&A down 25%."],"urls":{"canonical":"https://secwatch.observer/filing/0001493152-24-045354","json":"https://secwatch.observer/filing/0001493152-24-045354.json","markdown":"https://secwatch.observer/filing/0001493152-24-045354.md","text":"https://secwatch.observer/filing/0001493152-24-045354.txt","edgar_index":"https://www.sec.gov/Archives/edgar/data/926617/000149315224045354/0001493152-24-045354-index.htm","edgar_primary_document":"https://www.sec.gov/Archives/edgar/data/926617/000149315224045354/form8-k.htm"},"model":{"generated_by":"deepseek-v4-flash:cloud@v2","generated_at":"2026-05-30T00:43:14.024271+00:00"},"review":{"review_status":"machine_generated","human_reviewed":false,"corrected":false,"correction_note":null,"correction_timestamp":null,"superseded_by":null,"related_filings":[]},"source_grounded_claims":[],"license":"Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer"}